Europe Likes Schering’s Bridion, But Not Takeda’s Rozerem
This article was originally published in The Pink Sheet Daily
Executive Summary
New opinion includes CHMP skepticism of insomnia drug.
You may also be interested in...
Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee
After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.
Schering Plough’s Bridion Faces FDA Setback
Safety concerns render anesthesia injection “not approvable” in U.S.
Schering Plough’s Bridion Faces FDA Setback
Safety concerns render anesthesia injection “not approvable” in U.S.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: